Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis

David S Alberts, E. Hannigan, R. Canetta, R. O'Toole, V. Malviya, E. Surwit, W. Nahhas, C. Jolles, J. Jacobs, S. Pashko

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

By comparing treatment efficacy and cost, the authors evaluate the use of cisplatin and carboplatin for stage III or IV ovarian cancer. Differences in toxicity-related care, including hospitalizations, are investigated to ascertain the advisability of substituting one drug for another.

Original languageEnglish (US)
JournalP and T
Volume19
Issue number7
Publication statusPublished - 1994

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology

Cite this

Alberts, D. S., Hannigan, E., Canetta, R., O'Toole, R., Malviya, V., Surwit, E., ... Pashko, S. (1994). Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis. P and T, 19(7).